Forest's Lercanidipine Falls Short In Hypertension Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The calcium channel blocker "did not meet all the stringent preset criteria for dose response," and Forest plans to develop an alternative formulation. Company downgrades its earnings forecast following approval of Celexa generics; Forest's Inwood Labs division is marketing its own citalopram generic.